In breast cancer, blockade of PD-L1 and/or STAT3 signaling prevents γδ Treg-induced senescence, enhancing the human epidermal growth factor receptor 2 (HER2)-specific responses and immunotherapy efficacy (99). This evidence concerns the gene ERBB2 and breast cancer.